Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 250

Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Summary

This will be a placebo-controlled, multicenter-randomized prospective study of CPLE (Carica papaya leaf extract) tabs in dengue patients (WHO-Group A, B). The study will enroll 300 eligible dengue cases into two arms: one arm receiving CPLE 1000mg t.i.d for 5 days and the other group receiving a placebo. The main question to ask is whether CPLE reduces severe disease progression and increases platelet counts in dengue patients. The participant will be asked to take orally available CPLE capsules at a dose of 1000 mg (2 capsules, 500mg each) or identical placebo three times a day for 5 days

Eligibility Criteria

Inclusion Criteria: * Patients who are confirmed dengue fever by NS1 dengue Ag or anti dengue Ab IgM positive Exclusion Criteria: * Children (\150 U/L * Patient with serum creatine \>1.4 mg/dl * S. creatine kinase (CK) \>1000 U/L

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06121934). StuddyBuddy aggregates publicly available trial information.